Securities Code: 301201
Securities Abbreviation: Chengda Pharmaceutical
Announcement Number: 2026-018
Chengda Pharmaceutical Co., Ltd. announces that the information provided by its shareholder, Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership), holding more than 5% of shares, is true, accurate, and complete, with no false records, misleading statements, or significant omissions. The company and all members of the board guarantee that the announcement content is consistent with the information disclosed by the obligated party.
Special Reminder:
- The subject of this equity change is Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) (hereinafter referred to as "Qianhai Shengtai"). This equity change is due to a reduction in shareholding through block trades and centralized bidding, resulting in a decrease in shareholding ratio. According to the relevant provisions of the "Securities and Futures Legal Application Opinion No. 19 - <Management Measures for the Acquisition of Listed Companies> Articles 13 and 14," the obligated party's shareholding ratio has decreased to an integer multiple of 5%, changing from 10.00% to 5.00%.
- This equity change does not trigger a mandatory tender offer, will not lead to changes in the company's controlling shareholder or actual controller, and will not affect the company's governance structure and ongoing operations.
I. Basic Situation of the Equity Change
The company recently received a "Simplified Equity Change Report" issued by Qianhai Shengtai, which indicates that Qianhai Shengtai has cumulatively reduced its shareholding in the company by 7,752,149 shares through block trades and centralized bidding, changing its shareholding ratio from 10.00% to 5.00%.